2​ Biological Activity ICG-001 is a selective Wnt/β-catenin signalling inhibitor with an IC50 of 3μM. After selectively binding of ICG-001 to the NH2 terminus of cyclic AMP response element binding protein (CREB), ICG-001 prevented beta-catenin/TCF signaling. ICG-001 elevated the activities of caspase in colon carcinoma cell lines, but not normal cells via down regulation of survivin. It is exhibited that ICG-001 rescues defects in neuronal differentiation and reverse pulmonary fibrosis. ICG-001 also suppressed the interaction between CREB and γ-catenin. [1] ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells. And ICG-001 reduces in vitro growth of colon carcinoma cells. ICG-001 efficaciously treated the colon cancer in the Min mouse and nude mouse xenograft models. [2] 3​ References: ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Eguchi M et al. Med Chem. 2005 Sep;1(5):467-72. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Emami KH et al. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7. The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.